Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 21;14(11):e0224420. doi: 10.1371/journal.pone.0224420

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Giordano et al

This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

Fig 2 — (A), Combination index (CI) curves for the 6 cell lines treated with GSK461364 plus docetaxel or cisplatin. TNBC cell lines: SUM149, SUM159, SUM229, SUM1315 and DU4475 cells, and the non-tumorigenic human breast epithelial cell line MCF10A. TNBC cell lines were treated with the Plk1 inhibitor GSK461364 (g) at the IC₂₅ dose plus each chemotherapy drug (d, docetaxel; c, cisplatin) at the IC₅₀ concentration. (B), CI and DRI values for each combination of GSK461364 plus chemotherapy. CI and the dose-reduction index (DRI) values were determined using CompuSyn software. CI <1 indicates a synergism. DRI >1 indicates a favorable dose reduction.